Senti Biosciences shares surge 10.87% after-hours after completing Phase 1 trial enrollment for SENTI-202 in relapsed/refractory AML.

Senti Biosciences surged 10.87% in after-hours trading following the announcement that it completed enrollment in its Phase 1 clinical trial of SENTI-202 for relapsed or refractory acute myeloid leukemia. This milestone, reported seven days prior, marks a critical step in the therapy’s development, signaling progress toward evaluating its efficacy and safety in a targeted patient population. The stock’s strong after-hours performance aligns with the positive sentiment surrounding the trial’s completion, which reflects the company’s advancing pipeline and potential for regulatory milestones. Earlier events, such as the FDA’s RMAT designation and updated clinical data presentations, also contributed to sustained investor interest but were overshadowed by the recent enrollment news as the primary catalyst for the sharp price increase.